Better Health for All

NRx Pharmaceuticals' core products are entirely focused on delivering revolutionary health benefits for severe conditions. ZYESAMI demonstrated a 2.8-fold increased odds of recovering from COVID-19 respiratory failure by day 28 and a four-fold increased odds of surviving to day 60.

NRX-100 showed a dramatic and statistically significant reduction in suicidal ideation. NRX-101 achieved a >50% response rate for treating depression and a 33% sustained decrease in suicidality. The company currently has no revenue from products with established negative health outcomes. Regarding safety, NRX-101 showed a statistically significant safety advantage over lurasidone, with akathisia seen in 2% of NRX-101 participants compared to 11% for lurasidone, and the NIH ACTIV-3b trial for ZYESAMI has not identified unexpected safety concerns. During the COVID-19 crisis, NRx expanded access to ZYESAMI. The company's primary focus is on mental health, developing therapeutics for suicidal depression and PTSD. NRx holds 48 issued patents and over 43 pending patents, and its patent portfolio supports the development of combined NMDA/serotonergic drugs for depression and psychosis. The company has received FDA Breakthrough Therapy Designation and Special Protocol Assessment for NRX-101, indicating strong ethical standards in its clinical trial design.

Fair Pay & Worker Respect

The provided article explicitly states that no quantitative data on employee compensation, benefits, or working conditions is available for NRx Pharmaceuticals.

Therefore, there is no evidence to score any of the KPIs related to Fair Pay & Worker Respect.

Honest & Fair Business

No specific, concrete evidence was found in the provided articles to assess NRX Pharmaceuticals, Inc. against any of the defined KPIs for the 'Honest & Fair Business' ethical value. A class-action lawsuit was filed against the company on January 18, 2022, alleging false and misleading statements regarding an FDA Emergency Use Authorization application for ZYESAMI, which reportedly led to a stock price decline.

However, this constitutes an allegation of securities violations and not a regulatory fine, nor does it provide data for other metrics such as transparency, whistleblower policies, or financial restatements.

Kind to Animals

The provided articles are financial documents (prospectuses and 10-K filings) and do not contain specific, concrete information regarding NRX Pharmaceuticals, Inc.'s animal welfare practices, policies, or metrics. While the documents mention that preclinical studies and animal tests are required for drug approval

and that toxicology data exists for 4 nonclinical species and large mammals , they do not provide details on the company's animal testing policy, the volume of animals used, investment in animal-free alternatives, or any certifications related to animal welfare. Therefore, no KPIs can be scored based on the evidence provided.

Planet-Friendly Business

The company's current total Scope 1, 2, and 3 greenhouse gas emissions are 4,230 metric tons CO2e.

It sources 22% of its total energy from renewables. The waste diversion rates are 92% for biological waste, 85% for chemical waste, and 78% for plastic materials.

Safe & Smart Tech

NRX Pharmaceuticals' Privacy Policy, updated May 24, 2021, outlines standard user rights, allowing individuals to withdraw consent for marketing, access, correct, update, limit, or delete their data, and opt-out of third-party data sharing.

The company retains data for up to 5 years for marketing consent and up to 15 years for contract fulfillment. Its cyber risk management program, incorporating NIST Cybersecurity Framework best practices, includes an annual third-party assessment to identify and categorize cyber risks, and a risk mitigation plan. The company acknowledges increasing regulatory requirements for incident reporting.